GlaxoSmithKline PLC is poised to take back control of some of its biggest OTC brands in South Korea as part of a portfolio review triggered by the launch of its consumer healthcare joint venture with Pfizer Inc..
The UK-based firm has terminated ahead of schedule a sales and distribution deal with Dongwha Pharmaceutical in a move which...